欧洲泌尿外科学会原发性尿道癌指南2020更新
该指南由欧洲泌尿外科学会制定,基于系统检索更新了原发性尿道癌的诊断与治疗推荐。原发性尿道癌占泌尿生殖系统恶性肿瘤不足1%,尿路上皮癌最常见(54-65%)。指南涵盖诊断方法、病理分期及不同分期的治疗选择。
要点
- 原发性尿道癌罕见但侵袭性强,尿路上皮癌占54-65%。
- 局限远端肿瘤(≤T2N0M0)可考虑部分尿道切除或保留尿道手术。
- 局部晚期(≥T3N0-2M0)需多学科团队讨论,前列腺或近端≥T2N0可考虑新辅助顺铂化疗。
核心结论
- 该欧洲泌尿外科学会指南为疑似原发性尿道癌患者的当代诊断和管理提供了最新循证指导。
研究设计与样本
- 制定机构为欧洲泌尿外科学会,方法为系统检索Ovid(Medline)、EMBASE、Cochrane中央对照试验注册库和Cochrane系统综述数据库。
主要发现
- 尿道尿路上皮癌是原发性尿道癌最主要的组织学类型(54-65%),其次是鳞状细胞癌(16-22%)和腺癌(10-16%)。
关键数值与推荐
- 诊断依赖尿道膀胱镜检查加活检和尿细胞学。
- 病理分期和分级基于TNM分类和2016年世界卫生组织分级系统。
- 局部肿瘤范围和区域淋巴结通过磁共振成像评估,远处转移通过胸部/腹部和盆腔计算机断层扫描评估。
- 对于所有局限远端肿瘤(≤T2N0M0)患者,部分尿道切除或保留尿道手术是有效治疗选择,前提是术中手术切缘阴性。
- 前列腺Ta-Tis-T1原发性尿道癌可重复经尿道前列腺电切加卡介苗治疗。
临床怎么用
- 临床实践中应按指南推荐使用尿道膀胱镜、活检和尿细胞学进行诊断,并根据TNM和WHO分级进行病理评估。
- 根据肿瘤位置和分期选择保留尿道手术、经尿道电切加卡介苗、新辅助化疗后根治手术或放化疗等多模式治疗。
- 局部晚期患者应通过多学科团队讨论制定个体化方案,转移性患者根据肿瘤特征考虑系统治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Primary urethral carcinoma (PUC) is a rare cancer accounting for <1% of all genitourinary malignancies. OBJECTIVE: To provide updated practical recommendations for the diagnosis and management of PUC. EVIDENCE ACQUISITION: A systematic search interrogating Ovid (Medline), EMBASE, and the Cochrane Central Register of Controlled Trials and Cochrane Database of Systematic Reviews was performed. EVIDENCE SYNTHESIS: Urothelial carcinoma of the urethra is the predominant histological type of PUC (54-65%), followed by squamous cell carcinoma (16-22%) and adenocarcinoma (10-16%). Diagnosis of PUC depends on urethrocystoscopy with biopsy and urinary cytology. Pathological staging and grading are based on the tumour, node, metastasis (TNM) classification and the 2016 World Health Organization grading systems. Local tumour extent and regional lymph nodes are assessed by magnetic resonance imaging, and the presence of distant metastases is assessed by computed tomography of the thorax/abdomen and pelvis. For all patients with localised distal tumours (≤T2N0M0), partial urethrectomy or urethra-sparing surgery is a valid treatment option, provided that negative intraoperative surgical margins can be achieved. Prostatic Ta-Tis-T1 PUC can be treated with repeat transurethral resection of the prostate and bacillus Calmette-Guérin. In prostatic or proximal ≥ T2N0 disease, neoadjuvant cisplatin-based chemotherapy should be considered prior to radical surgery. All patients with locally advanced disease (≥T3N0-2M0) should be discussed within a multidisciplinary team. In men with locally advanced squamous cell carcinoma, curative radiotherapy combined with radiosensitising chemotherapy can be offered for definitive treatment and genital preservation. In patients with local urethral recurrence, salvage surgery or radiotherapy can be offered. For patients with distant metastatic disease, systemic therapy based on tumour characteristics can be evaluated. CONCLUSIONS: These updated European Association of Urology guidelines provide up-to-date guidance for the contemporary diagnosis and management of patients with suspected PUC. PATIENT SUMMARY: Primary urethral carcinoma (PUC) is a very rare, but aggressive disease. These updated European Association of Urology guidelines provide evidence-based guidance for clinicians treating patients with PUC.
引用
- Gakis G, Bruins HM, Cathomas R, et al. European Association of Urology Guidelines on Primary Urethral Carcinoma-2020 Update. Eur Urol Oncol. 2020. PMID: 32605889. doi:10.1016/j.euo.2020.06.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。